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or Endogenous Parathyroid Hormone
Vit Zikan and Jan J. Stepan
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Medicine, Prague, Czech Republic.
Abstract: Parathyroid hormone (PTH) changes morphology of osteoclasts within minutes after its systemic administration. The 
aim of our study was to test in healthy men whether both exogenous and endogenous PTH could change acutely (minutes to 
hours) the serum cross-linked C-telopeptide of type I collagen (beta CTX), which is released during osteoclastic resorption of 
bone. Twelve healthy men (age range 24–34 yr) were each studied during 180 min on a control period, after a single subcutane-
ous injection of teriparatide, and after 30 min EDTA infusion to stimulate endogenous PTH secretion. The tests were started after 
overnight fast, 3 h after a standard calcium load. The EDTA infusion induced a significant decrease in serum ionized calcium 
(by 8.5% at 33 min) and a significant increase in plasma PTH (by 305% at 33 min). Both the EDTA and teriparatide resulted in 
a significant increase in beta CTX (p  0.001) with maximum increases of 64% and 80%, respectively. A mild, but significant 
decrease in beta CTX was observed during the control test period. In conclusion, single-dose teriparatide injection as well as a 
stimulation of endogenous PTH in healthy men results in an acute increase of the bone resorption marker.
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Parathyroid hormone (PTH) increases bone resorption by stimulating both the appearance of new 
osteoclasts and the activity of mature osteoclasts (Suda et al. 1996; Morony et al. 1999). The effects of 
PTH on osteoclasts require the participation of stromal cells or osteoblasts which possess high-affinity 
PTH receptors, although also low-affinity receptors have been identified on osteoclasts (Gay et al. 
2003). Experimentally, rapid morphologic changes were documented in preexisting osteoclasts after a 
single exposure to PTH (Holtrop and King, 1977; Miller, 1978; Holtrop et al. 1979). In young rats, an 
intravenous injection of PTH resulted in morphological changes of osteoclasts within 30 minutes. These 
changes coincided with a small increase in plasma calcium concentration (Holtrop et al. 1979), and 
preceded increase in osteoclast numbers. In humans, the acute (minutes to hours) responses of bio-
chemical markers of bone resorption to a single dose of PTH were not observed by using the urinary 
hydroxyproline and deoxypyridinoline (Lindsay et al. 1993; Schwietert et al. 1997). Although, in the 
study of Lindsay et al. on 11 postmenopausal osteoporotic women, a single subcutaneous administration 
of human PTH (1–34) resulted in a rise of serum calcium concentrations (between 90–240 min), at the 
same time when serum phosphorus concentrations started to return to normal, despite the continuing 
increase in a phosphate clearance (Lindsay et al. 1993).
The aim of our study was to test in healthy men whether PTH both exogenous (as a single subcutaneous 
injection of teriparatide) and endogenous (induced by an acute hypocalcaemia), could change acutely (min-
utes to hours) the serum concentrations of mature collagen type I degradation fragments (beta CTX) (Rosen-
quist et al. 1998), the marker which is released into the circulation during osteoclastic resorption of bone.
Materials and Methods
Subjects
Twelve healthy men on no medication, mean age 27.7 ± 3.6 years (range 24–34 years), mean height of 
184.2 ± 4.9 cm, and mean weight 82.6 ± 9.2 kg participated in this study. The baseline blood pressure, 
physical examination and electrocardiogram were normal. All subjects were Caucasians and non-smokers. 20
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All subjects gave their signed informed consent 
and the study had been previously approved by the 
Ethics Committee of the First Medical Faculty, 
Charles University and General Faculty Hospital, 
Prague.
Study design
Twelve men were studied in three sessions 
7–14 days apart. The subjects fasted overnight, 
and for safety reasons and to standardize the 
baseline concentrations of the variables, all tests 
were performed 3 h after a standard calcium load 
(250 mg of elemental calcium in 200 ml of plain 
water and 30 g of white bread). The maximum 
decrease in bone resorption occurs approximately 
3 hours after such a calcium load (Zikan et al. 
2001). All subjects had been instructed to use the 
standard calcium load at 6:00 and to report time 
of calcium use.
An intravenous cannula was placed in the 
forearm and was used for both the EDTA infusion 
and blood sampling. Blood samples were obtained 
immediately before the test 3 h after a standard 
calcium load—approximately at 09:00 (baseline) 
and exactly at 33, 60, 90, 120 and 180 min after 
the beginning of the test. The subjects remained 
fasting until the end of each study session with 
steady intake of plain water (about 500 ml). The 
plasma and serum specimens were stored at 
−70 ºC for the later measurement of the bone 
markers and PTH. Measurement of the serum 
ionized calcium (iCa) was performed on the same 
day after anaerobic collection (Vacutainer
®) of 
all specimens, which were stored at 4 ºC to avoid 
pH shifts.
The endogenous PTH secretion was stimulated 
by hypocalcaemia induced by an EDTA infusion. 
Disodium ethylenediaminetetraacetic acid (EDTA) 
at a dose of 10 mg/kg body weight in 100 ml 0.9% 
NaCl solution was administered for 30 min, along 
with 10–15 ml of 10% trimecaine in 100 ml 0.9% 
NaCl to avoid the venous irritation and followed 
by 20 ml 0.9% NaCl alone over 1 min after the end 
of EDTA infusion.
Human recombinant PTH 1–34, teriparatide 
(Forsteo
®, Eli Lilly, Indianapolis, U.S.A.) at a dose 
of 20 μg was administered as a single injection 
subcutaneously into the anterior abdominal wall. 
Only plain water was given after a standard calcium 
load during the control test period.
Biochemical analysis
All samples, except the serum ionized calcium, 
were assayed simultaneously. Serum ionized cal-
cium (iCa) was measured using ion selective elec-
trode with an AVL 9180 (Roche Diagnostics GmbH, 
Germany). The within run imprecision was below 
2% and between run imprecision was below 4%.
The plasma concentrations of the immunoreac-
tive intact PTH were determined using an 
electrochemiluminesce—based immunoanalysis 
(the Elecsys 1010 Analyzer, Roche Diagnostics 
GmbH, Germany). The within run imprecision was 
below 6%.
The serum concentrations of type I collagen 
cross-linked C telopeptide (CTX; beta CrossLaps) 
and N-MID osteocalcin (OC) in the plasma was 
assessed using the electrochemiluminiscence—
based immunoanalysis (the Elecsys 1010 Analyzer, 
Roche Diagnostics, Germany). The within run 
imprecision for the CTX was below 7%. The within 
run imprecision for the OC was below 5%.
The serum concentration of intact aminotermi-
nal propeptide of type I procollagen (PINP) was 
assessed by radioimmunoassay (Procollagen Intact 
PINP, Orion Diagnostica, Finland). The within run 
imprecision was below 5%.
Serum 25-hydroxyvitamin D3 (25-OHD3) was 
determined using radioimmunoassay (OCTEIA-25-
hydroxy Vitamin D kit, Immunodiagnostic Systems 
Limited, U.K.) with the normal range of 47.7–144 
nmol/l. The between run imprecision was 8.2%.
Statistical analysis
Data were expressed as mean ± SD if not otherwise 
stated. The time differences were assessed by one-
way ANOVA for repeated measurements. If the 
treatment effects were not normally distributed, 
the Friedman repeated measures ANOVA on ranks 
was used. If a significant difference was found with 
ANOVA, subsequent multiple comparison proce-
dures (Tukey test) were used to determine the 
difference between the basal values and other time 
points. The trapezoidal rule was used to calculate 
the area under the curve (AUC) for the measured 
biochemical parameters. The differences between 
the study sessions were evaluated by the paired t 
test or ANOVA. Analyses were made with Sigma-
Stat statistical software, version 3.1 (Jandel Cor-
poration, San Rafael, U.S.A). The differences are 
considered significant at p  0.05.21
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Results
The initial (fasting) concentrations of the measured 
biochemical variables (mean ± 1 SD) were as fol-
lows: serum iCa, 1.31 ± 0.02 mmol/l; plasma PTH, 
30.3 ± 6 ng/l; serum 25-OHD3, 52.8 ± 10 nmol/l; 
serum beta CTX, 485.6 ± 133 ng/l; plasma 
osteocalcin, 24.3 ± 6 μg/l; serum PINP, 64.8 ± 17 
μg/l. All results were within normal age- and sex- 
range. All subjects completed the full study proto-
col with no adverse event.
Figure 1 shows the mean percentage changes in 
serum iCa (A) and plasma intact PTH (B) during 
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Figure 1. A. Mean percentage changes (± SEM) in serum ionized calcium concentrations in response to EDTA infusions (Δ) and teriparatide 
injections (•) in 12 studied men. During the control test period only a standard calcium load was consumed (̆). 
a, p  0.001 repeated mea-
sures ANOVA and p  0.05 for comparison with baseline after adjustments for multiple comparisons (Tukey test). 
b, p  0.05, t-test for 
comparison AUCs between teriparatide and control test period. B. Mean percentage change (± SEM) in plasma intact PTH concentration 
in response to EDTA infusions in 12 studied men. 
a, p  0.001 Friedman repeated measures ANOVA  on ranks and p  0.05 for comparison 
with baseline after adjustments for multiple comparisons (Dunn´s Method). Hatched area represents EDTA infusion.22
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the control and 2 study periods in all 12 subjects. 
After the EDTA infusion, there was a significant 
decrease in serum iCa from a baseline value of 
1.32 ± 0.03 mmol/l to 1.21 ± 0.04 mmol/l as early 
as at 33 min and the decrease remained significant 
until the end of observation at 180 min (RM 
ANOVA, p  0.001; Tukey test, p  0.05 for all 
time points versus baseline) (Fig. 1A). No signifi-
cant changes in serum iCa were detected following 
teriparatide administration compared to baseline 
(RM ANOVA, p = 0.235). However, as compared 
to the control test period, serum iCa was signifi-
cantly higher at 180 min after teriparatide injection 
(1.33 ± 0.03 mmol/l and 1.28 ± 0.02 mmol/l, terip-
aratide and control period, respectively). During the 
control test period, there was a mild, but significant 
decrease in serum iCa from a baseline value of 1.32 
± 0.02 to 1.28 ± 0.02 mmol/l at 180 min (RM 
ANOVA, p  0.001; Tukey test, p  0.05).
The hypocalcaemia induced by the infusion of 
EDTA caused a transient increase in plasma intact 
PTH from a baseline value of 27 ± 16 ng/l to a peak 
value of 98 ± 38 ng/l after the end of the 30 min 
infusion (at 33 min), with subsequent rapid 
decrease near to the baseline values (Fig. 1B). 
Concentrations of human PTH 1–34 peptide were 
not measured in this study. However, a peak of the 
peptide occurs at about 30 minutes after human 
PTH 1–34 administration (Lindsay et al. 1993).
Mean changes in the concentrations of serum 
beta CTX from the beginning to the end of the study 
periods in all 12 subjects are shown in Figure 2 
(mean percentage changes) and in the Table 1 (mean 
absolute values). The time course for the increase 
in beta CTX concentrations was highly reproduc-
ible in all subjects for both the teriparatide injec-
tions and EDTA infusions. Both the EDTA and 
teriparatide resulted in a significant increase in beta 
CTX (RM ANOVA, p  0.001; Tukey test, p  0.05 
for 60–180 min) with maximum increases of 64% 
and 80%, respectively. There were no significant 
differences between the AUCs for teriparatide injec-
tions and AUCs for EDTA infusions. During the 
control test period, there was a mild, but statistically 
significant decrease in serum beta CTX as early as 
at 60 min (RM ANOVA, p  0.001; Tukey test, 
p  0.05 for 60–180 min). There were significant 
differences between the AUCs for control test 
period and AUCs for teriparatide injections or 
EDTA infusions (ANOVA, p  0.001).
Plasma N-MID osteocalcin and serum PINP, 
markers of bone formation, remained stable over 3 h 
of study period after both PTH and EDTA adminis-
trations in five studied men (data not shown).
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Figure 2. Mean percentage changes (± SEM) in serum beta CTX concentrations in response to EDTA infusions (Δ) and teriparatide injec-
tions (•) in 12 studied men. During the control test period only a standard calcium load was consumed (̆). 
a, p  0.001 repeated measures 
ANOVA and p  0.05 for comparison with baseline after adjustments for multiple comparisons (Tukey test). 
b, p  0.001, ANOVA for com-
parison AUCs between teriparatide or EDTA and control test period. Hatched area represents EDTA infusion.23
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Discussion
We demonstrated that in healthy young men both 
the transient stimulation of endogenous PTH 
secretion and the single subcutaneous administration 
of teriparatide increased serum beta CTX concentra-
tion, the degradation product of mature collagen 
type I, which is released into the circulation during 
osteoclastic bone resorption. In accordance with 
known circadian variation in bone resorption, a mild 
but significant decrease in the serum beta CTX 
concentration was observed during the control test 
period. The rapid increase in the serum beta CTX 
concentration as early as 1 hour in response to PTH 
suggests that PTH affects the function of mature 
active osteoclasts. This is consistent with previous 
morphological evidence of changes in activity of 
resorbing osteoclasts within minutes after exposure 
to hormone (Holtrop et al. 1979; Miller, 1978).
The rapid increase in serum beta CTX concentra-
tions seems to reflect the secretion activity of 
osteoclasts. Resorbing osteoclasts are dynamic cells 
with a high membrane turnover which have specific 
machinery for uptake and transcytosis of bone 
degradation products, such as type I collagen frag-
ments (Nesbitt and Horton, 1997; Salo et al. 1997). 
Once resorption has started, endocytosis and tran-
scytosis of the endocytosed material from the ruf-
fled border of osteoclast are fast processes, which 
cover the speed requirements of the large membrane 
turnover during bone resorption (Stenbeck and 
Horton, 2004). Also, PTH may control transport 
processes of bone degradation products through the 
lining bone cell complex from the bone fluid com-
partment to the circulation (Talmage et al. 1976).
The osteoclast-mediated resorption may be 
involved in the initial phase of PTH anabolic action 
on bone (Onyia et al. 2000; Martin and Sims, 
2005). Experimental data indicated that active 
osteoclasts are required within one hour after PTH 
administration for the full anabolic effect of PTH 
to be achieved (Gooi et al. 2006). The anabolic 
effect of PTH is blunted by treatment with bone 
resorption inhibitors such as bisphosphonates 
(Delmas et al. 1995; Wronski et al. 1993; Finkelstein 
et al. 2003). As expected, during the period of 
3 hours there was no apparent effect of PTH admin-
istration on markers of bone formation at least in 
five studied men. A more prolonged period of 
obeservation should be needed to observe changes 
in these markers of bone formation.
The present study has several important limita-
tions. Our subjects were healthy young men and 
the results do not allow conclusions concerning 
osteoporotic patients. Separate tests in this study 
were performed sequentially and in open label. We 
did not measure plasma kinetics of the amino ter-
minal peptide (hPTH 1–34) after teriparatide 
administration; therefore it is not possible to com-
pare the plasma profile of teriparatide with the 
endogenous PTH concentrations. However, it has 
been shown that teriparatide concentration peaks 
about 30 min after its single administration 
(Lindsay et al. 1993). The observed rapid change 
in serum beta CTX concentrations seems to reflect 
the secretion activity of osteoclasts. However, we 
did not measure directly osteoclast activity and our 
assumption is based primarily on previously pub-
lished reports of animal experimentation.
In conclusion, single teriparatide administration 
as well as stimulation of endogenous PTH results 
in an acute increase in the bone resorption, as 
assessed by serum beta CTX. Our data support the 
concept that, in the initial rapid phase of PTH 
action on bone, osteoclast-mediated resorption is 
involved. Serum beta CTX seems to be a useful 
biochemical marker in the monitoring of acute 
effect of PTH on bone resorption.
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Table 1. Mean changes (1 SD) in serum beta CTX concentrations (ng/l) in response to EDTA infusions, teripa-
ratide injections and control test period after a standard calcium load in 12 men.
Period
(N = 12)  baseline  30 min  60 min  90 min  120 min  180 min
Control   441 (138)  389 (115)  376 (132)*  373 (158)*  356 (141)*  371(141)*
Teriparatide  349 (120)  319 (128)  458 (141)*  533 (152)*  554 (146)*  611 (186)*#
EDTA  330 (126)  333 (124)  436 (146)*  508 (147)*  510 (150)*  481 (134)*#
*, p  0.001 repeated measures ANOVA and p  0.05 for comparison with baseline after adjustments for multiple comparisons (Tukey 
test). #, p  0.001, ANOVA for comparison AUCs between teriparatide or EDTA and control test period.24
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